Bank of America has revised its 2026 stock price projection for Hims & Hers, reducing it from $23 to $21. The financial institution maintains a 'Neutral' rating on the stock, attributing the adjustment to a combination of compression in peer valuations and expected short-term earnings hurdles. The company's strategic move towards branded GLP-1 (Glucagon-like Peptide-1) treatments and its international market penetration initiatives are cited as key factors influencing these financial outlooks.

Hims & Hers shares experienced a notable decline of nearly 39% this year, trading around $20. Analysts anticipate that the company's EBITDA for 2026 could fall approximately 20% below the current market consensus. Furthermore, the contribution from GLP-1 products to the company's EBITDA might decrease by as much as 50% year-over-year. This projection underscores the significant uncertainty surrounding the company's near-term profitability.

The transition to branded GLP-1 offerings and the expansion into international markets are expected to impact profit margins negatively. Although this strategic pivot is seen as a move towards building a more sustainable business model, it is likely to incur short-term margin headwinds as existing investments are reallocated or scaled back. For instance, the firm's assessment of the Eucalyptus platform indicates that a substantial portion of its revenue, around 90%, is expected to come from branded GLP-1 distribution, operating at a gross margin of approximately 40%.

Despite these immediate concerns, Bank of America identifies promising growth opportunities within the branded segment and international expansion. The $149-per-month branded GLP-1 plan is believed to have the potential to generate similar EBITDA per subscriber as compounded offerings over time. However, the success of this plan hinges on the rate at which customers transition from the lower-cost model. Analysts estimate that 40% to 50% of current subscribers could convert to branded plans, with an additional 5-10% retaining compounded offerings, potentially generating $60 million to $90 million in quarterly GLP-1 revenue, augmented by cash-pay subscribers.

International growth is also a significant avenue for expansion, with Hims & Hers aiming to increase its global business to over $1 billion within the next three years, targeting a mid-teens organic Compound Annual Growth Rate (CAGR). While a half-year contribution from the Eucalyptus platform might initially lead to a slight EBITDA margin reduction of 1 to 2 percentage points, operating at a low single-digit EBITDA margin loss, there is considerable potential for margin improvement in the long run as the platform matures and integrates more effectively.

The revised price target for Hims & Hers by Bank of America reflects a cautious but optimistic outlook. While the company faces short-term financial pressures and margin challenges due to its strategic shift towards branded GLP-1 products and international market expansion, the underlying potential for sustainable growth in these new segments remains a key consideration. The ability of Hims & Hers to effectively manage this transition and attract a significant portion of its customer base to higher-margin branded offerings will be crucial for its future financial performance.